Heritage and Innovation Come Together1-3
VALTOCO is a reliable nasal spray that was carefully formulated to address the principal limitations of intranasal drug delivery.1,2
Nearly complete absorption

bioavailability relative to intravenous diazepam1,4,5
VALTOCO combines the established history of diazepam with novel formulation technology.1,3,6
Optimized for Nasal Delivery1,7
Diazepam
- Recognized as a safe and effective seizure treatment for more than 50 years1,3
- Has been prescribed as a seizure rescue treatment for nonmedical care partner use for >20 years8,9
- Highly lipophilic molecule readily crosses the blood-brain barrier10,11
- Half-life contributes to sustained plasma levels1
Intravail®
- Designed to increase bioavailability and reliability of nasal drug delivery2,12
- Generally safe, non-toxic substance12
- Facilitates increased drug absorption across the nasal mucosa in 2 ways2,12:
- Increases permeability of cell membranes2,12
- Temporarily loosens tight junctions between cells, allowing the drug to pass through2,12
Vitamin E
- Primary solvent provides adequate drug concentration within a small liquid volume13
- Coats the nasal cavity14,15
Inactive ingredients: benzyl alcohol, dehydrated alcohol, n-dodecyl beta-D-maltoside, vitamin E.1
Reliable Absorption With Sustained Plasma Levels Throughout the Day1,4,5
Pharmacokinetic (PK) studies were conducted in patients with epilepsy and healthy volunteers1
- 97% absolute bioavailability relative to IV diazepam1,4,5
- Plasma levels sustained for 24 hours1
- Predictable PK with low interpatient and intrapatient variability1
- Diazepam PK 2- to 4-fold less variable than diazepam rectal gel regardless of patient weight1,16
Nasal spray administration coupled with the proprietary VALTOCO formulation account for key PK differences vs IV diazepam1,4,5

Seizure clusters occur over a 24-hour period17
Data from an open-label, crossover study of the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration to healthy volunteers (N=24) under fasted conditions (Study 01).
Efficacy Based on Comparable Bioavailability to Diazepam Rectal Gel
VALTOCO has demonstrated comparable bioavailability to diazepam rectal gel, an established formulation of diazepam, approved by the FDA in 1997 for the intermittent treatment of bouts of increased seizure activity in children and adults.1,18,19 The efficacy of diazepam rectal gel was demonstrated in 2 randomized, placebo-controlled trials.20,21 As a result, the FDA allowed for the utilization of diazepam rectal gel efficacy data in support of the approval of VALTOCO.22,23
See How VALTOCO Works
Learn how the unique formulation of VALTOCO® (diazepam nasal spray) optimizes diazepam for nasal delivery, and how it helps patients manage episodes of frequent seizure activity wherever, whenever.1,7
